While liquiritigenin, isolated from Spatholobus suberectus Dunn, is known to possess anti-inflammatory activities, it still remains to be known whether liquiritigenin has a suppressive effect on T cell activation and T cell-mediated disease. Here, we used Jurkat T cells to explore an underlying mechanism of pre-treatment with liquiritigenin in activated T cell in vitro and used atopic dermatitis (AD) in vivo to confirm it. We found liquiritigenin blocks IL-2 and CD69 expression from activated T cells by PMA/A23187 or anti-CD3/CD28 antibodies. The expressions of surface molecules, including CD40L and CD25, were also reduced in activated T cells pre-treated with liquiritigenin. Western blot analysis indicated repressive effects by liquiritigenin are involved in NFκB and MAPK pathways. To assess the effects of liquiritigenin in vivo, an AD model was applied as T cell-mediated disease. Oral administration of liquiritigenin attenuates AD manifestations, including ear thickness, IgE level, and thicknesses of dermis and epidermis. Systemic protections by liquiritigenin were observed to be declined in size and weight of draining lymph nodes (dLNs) and expressions of effector cytokines from CD4+ T cells in dLNs. These results suggest liquiritigenin has an anti-atopic effect via control of T cell activation and exhibits therapeutic potential for T cell-mediated disorders.

中文翻译：

---

Liquiritigenin的口服给药可通过抑制T细胞活化来预防特应性皮炎。

尽管已知分离自皮下鸡血藤（Spatholobus suberectus Dunn）的liquiritigenin具有消炎活性，但liquiritigenin是否对T细胞活化和T细胞介导的疾病具有抑制作用仍是未知的。在这里，我们使用Jurkat T细胞来探索在体外活化T细胞中用liquiritigenin进行预处理的潜在机制，并在体内使用特应性皮炎（AD）进行确认。我们发现，liquiritigenin可以阻止PMA / A23187或抗CD3 / CD28抗体激活的T细胞中IL-2和CD69的表达。在用liquiritigenin预处理的活化T细胞中，包括CD40L和CD25在内的表面分子的表达也降低了。蛋白质印迹分析表明，liquiritigenin的抑制作用与NFκB和MAPK通路有关。为了评估Liquiritigenin在体内的作用，AD模型被用作T细胞介导的疾病。口服Liquiritigenin可减轻AD表现，包括耳朵厚度，IgE水平以及真皮和表皮厚度。观察到由liquiritigenin进行的全身性保护减少了引流淋巴结（dLNs）的大小和重量以及dLNs中CD4 + T细胞的效应细胞因子的表达。这些结果表明，liquiritigenin通过控制T细胞活化具有抗特应性作用，并具有治疗T细胞介导的疾病的潜力。观察到由liquiritigenin进行的全身性保护减少了引流淋巴结（dLNs）的大小和重量以及dLNs中CD4 + T细胞的效应细胞因子的表达。这些结果表明，liquiritigenin通过控制T细胞活化具有抗特应性作用，并具有治疗T细胞介导的疾病的潜力。观察到由liquiritigenin进行的全身性保护减少了引流淋巴结（dLNs）的大小和重量以及dLNs中CD4 + T细胞的效应细胞因子的表达。这些结果表明，liquiritigenin通过控制T细胞活化具有抗特应性作用，并具有治疗T细胞介导的疾病的潜力。